Table 1

Dose and duration of denosumab for treating spinal GCT

First authorLocationDoseDuration
(months)		ResultsSide effects
Duan P-G et al9T11 and T12 vertebraNot reported12No progression with calcification and regression of tumourNot reported
Law GW et al17C3 vertebra120 mg monthly for 9 months and every 2 months for 1 year21No progression during treatment, Disease progression at 6 months after stop denosumabNot reported
Goldschlager T et al4C, T and L vertebra120 mg monthly with initial loading dose on days 8 and 156No progression with calcification and regression of tumourNone
Nakazawa T et al18C5 vertebra120 mg monthly24Surrounding sclerosis and regression of tumourNone
Mattei TA et al19C2 vertebra120 mg weekly for 3 weeks then 120 mg monthly16Newly formed cortical bone with regression of tumourNone
Bukata SV et al20C, T, and L vertebra120 mg monthly with initial loading dose on days 8 and 1534–74Complete response 12.6%, partial response 35.9%, stable 50.5%, and progression 1%ONJ, AFF, hypercalcemia

  • AFF, atypical femoral fracture; C, cervical; GCT, giant cell tumour; L, lumbar; ONJ, osteonecrosis of the jaw; T, thoracic.